Last updated on July 2017

A Study of PEG-somatropin in the Treatment of Children With Idiopathic Short Stature


Brief description of study

This study aims to explore the optimal dose of pegylated recombinant human growth hormone (PEG-rhGH) injection to treat children with idiopathic short stature (ISS), evaluate its safety and efficacy, and provide scientific and reliable evidence for the medication dosage in Phase III clinical study.

Clinical Study Identifier: NCT03221088

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Xiaoping Luo, PhD

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
  Connect »

Yuhua Hu, MD

The First Affiated Hospital of Nanjing Medical University
Nanjing, China
  Connect »

Zhuangjian Xu, MD

Affiliated Hospital of Jiangnan University
Wuxi, China
  Connect »

Hongwei Du, MD

The First Hospital of Jilin University
Changchun, China
  Connect »

Junfen Fu, MD

The Children's Hospital of Zhejiang University School of Medicine
Hangzhou, China
  Connect »

Feihong Luo, MD

Shanghai Children's Hospital of Fudan University
Shanghai, China
  Connect »

Pin Li, MD

Shanghai Children's Hospital
Shanghai, China
  Connect »